165 related articles for article (PubMed ID: 37633797)
1. Hepatic fatty acid and glucose handling in metabolic disease: Potential impact on cardiovascular disease risk.
Westcott F; Dearlove DJ; Hodson L
Atherosclerosis; 2024 Jul; 394():117237. PubMed ID: 37633797
[TBL] [Abstract][Full Text] [Related]
2. Insulin resistance and central obesity determine hepatic steatosis and explain cardiovascular risk in steatotic liver disease.
Semmler G; Balcar L; Wernly S; Völkerer A; Semmler L; Hauptmann L; Wernly B; Aigner E; Niederseer D; Datz C
Front Endocrinol (Lausanne); 2023; 14():1244405. PubMed ID: 37842290
[TBL] [Abstract][Full Text] [Related]
3. Tcf7l2 in hepatocytes regulates de novo lipogenesis in diet-induced non-alcoholic fatty liver disease in mice.
Lee DS; An TH; Kim H; Jung E; Kim G; Oh SY; Kim JS; Chun HJ; Jung J; Lee EW; Han BS; Han DH; Lee YH; Han TS; Hur K; Lee CH; Kim DS; Kim WK; Park JW; Koo SH; Seong JK; Lee SC; Kim H; Bae KH; Oh KJ
Diabetologia; 2023 May; 66(5):931-954. PubMed ID: 36759348
[TBL] [Abstract][Full Text] [Related]
4. Metabolic-Dysfunction-Associated Steatotic Liver Disease-Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments.
Yanai H; Adachi H; Hakoshima M; Iida S; Katsuyama H
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895151
[TBL] [Abstract][Full Text] [Related]
5. Human skin stem cell-derived hepatic cells as in vitro drug discovery model for insulin-driven de novo lipogenesis.
Buyl K; Vrints M; Fernando R; Desmae T; Van Eeckhoutte T; Jans M; Van Der Schueren J; Boeckmans J; Rodrigues RM; De Boe V; Rogiers V; De Kock J; Beirinckx F; Vanhaecke T
Eur J Pharmacol; 2023 Oct; 957():175989. PubMed ID: 37572939
[TBL] [Abstract][Full Text] [Related]
6. Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease.
Smith GI; Shankaran M; Yoshino M; Schweitzer GG; Chondronikola M; Beals JW; Okunade AL; Patterson BW; Nyangau E; Field T; Sirlin CB; Talukdar S; Hellerstein MK; Klein S
J Clin Invest; 2020 Mar; 130(3):1453-1460. PubMed ID: 31805015
[TBL] [Abstract][Full Text] [Related]
7. Semaglutide Improves Liver Steatosis and De Novo Lipogenesis Markers in Obese and Type-2-Diabetic Mice with Metabolic-Dysfunction-Associated Steatotic Liver Disease.
Soto-Catalán M; Opazo-Ríos L; Quiceno H; Lázaro I; Moreno JA; Gómez-Guerrero C; Egido J; Mas-Fontao S
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474208
[TBL] [Abstract][Full Text] [Related]
8. Fructose as a key player in the development of fatty liver disease.
Basaranoglu M; Basaranoglu G; Sabuncu T; Sentürk H
World J Gastroenterol; 2013 Feb; 19(8):1166-72. PubMed ID: 23482247
[TBL] [Abstract][Full Text] [Related]
9. Type 2 diabetes mellitus and cardiometabolic outcomes in metabolic dysfunction-associated steatotic liver disease population.
Chew NWS; Pan XH; Chong B; Chandramouli C; Muthiah M; Lam CSP
Diabetes Res Clin Pract; 2024 May; 211():111652. PubMed ID: 38574897
[TBL] [Abstract][Full Text] [Related]
10. Hepatic saturated fatty acid fraction is associated with de novo lipogenesis and hepatic insulin resistance.
Roumans KHM; Lindeboom L; Veeraiah P; Remie CME; Phielix E; Havekes B; Bruls YMH; Brouwers MCGJ; Ståhlman M; Alssema M; Peters HPF; de Mutsert R; Staels B; Taskinen MR; Borén J; Schrauwen P; Schrauwen-Hinderling VB
Nat Commun; 2020 Apr; 11(1):1891. PubMed ID: 32312974
[TBL] [Abstract][Full Text] [Related]
11. The adipokine sFRP4 induces insulin resistance and lipogenesis in the liver.
Hörbelt T; Knebel B; Fahlbusch P; Barbosa D; de Wiza DH; Van de Velde F; Van Nieuwenhove Y; Lapauw B; Thoresen GH; Al-Hasani H; Müller-Wieland D; Ouwens DM; Kotzka J
Biochim Biophys Acta Mol Basis Dis; 2019 Oct; 1865(10):2671-2684. PubMed ID: 31336149
[TBL] [Abstract][Full Text] [Related]
12. Hepatic selective insulin resistance at the intersection of insulin signaling and metabolic dysfunction-associated steatotic liver disease.
Bo T; Gao L; Yao Z; Shao S; Wang X; Proud CG; Zhao J
Cell Metab; 2024 May; 36(5):947-968. PubMed ID: 38718757
[TBL] [Abstract][Full Text] [Related]
13. Role of Glucocorticoids in Metabolic Dysfunction-Associated Steatotic Liver Disease.
Polyzos SA; Targher G
Curr Obes Rep; 2024 Jun; 13(2):242-255. PubMed ID: 38459229
[TBL] [Abstract][Full Text] [Related]
14. Fructose drives de novo lipogenesis affecting metabolic health.
Geidl-Flueck B; Gerber PA
J Endocrinol; 2023 May; 257(2):. PubMed ID: 36753292
[TBL] [Abstract][Full Text] [Related]
15. Hepatic lipid accumulation: cause and consequence of dysregulated glucoregulatory hormones.
Geisler CE; Renquist BJ
J Endocrinol; 2017 Jul; 234(1):R1-R21. PubMed ID: 28428362
[TBL] [Abstract][Full Text] [Related]
16. Acyl-Coenzyme A Thioesterase 9 Traffics Mitochondrial Short-Chain Fatty Acids Toward De Novo Lipogenesis and Glucose Production in the Liver.
Steensels S; Qiao J; Zhang Y; Maner-Smith KM; Kika N; Holman CD; Corey KE; Bracken WC; Ortlund EA; Ersoy BA
Hepatology; 2020 Sep; 72(3):857-872. PubMed ID: 32498134
[TBL] [Abstract][Full Text] [Related]
17. Gracilaria chorda subcritical water ameliorates hepatic lipid accumulation and regulates glucose homeostasis in a hepatic steatosis cell model and obese C57BL/6J mice.
Thakuri LS; Park CM; Kim HA; Kim HJ; Park JW; Park JC; Rhyu DY
J Ethnopharmacol; 2024 Feb; 320():117395. PubMed ID: 37952731
[TBL] [Abstract][Full Text] [Related]
18. De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose.
Sanders FW; Griffin JL
Biol Rev Camb Philos Soc; 2016 May; 91(2):452-68. PubMed ID: 25740151
[TBL] [Abstract][Full Text] [Related]
19. Fructose Consumption, Lipogenesis, and Non-Alcoholic Fatty Liver Disease.
Ter Horst KW; Serlie MJ
Nutrients; 2017 Sep; 9(9):. PubMed ID: 28878197
[TBL] [Abstract][Full Text] [Related]
20. Genetic Ablation of STE20-Type Kinase MST4 Does Not Alleviate Diet-Induced MASLD Susceptibility in Mice.
Caputo M; Andersson E; Xia Y; Hou W; Cansby E; Erikson M; Lind DE; Hallberg B; Amrutkar M; Mahlapuu M
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
